Latest Posts › Genetic Materials

Share:

Examination of Myriad-Mayo Guidance Comments -- The Coalition for 21st Century Medicine -- Part II

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

12/3/2014 - Coalition for 21st Century Medicine Draft Guidance Genetic Materials Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

BIO IPCC Panel Discusses Impact of Myriad-Mayo Guidance

Yesterday, we reported on a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsel's Committee fall conference, which took place earlier this week in Nashville, TN, in which the U.S. Patent and...more

11/14/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical USPTO

USPTO Provides Update on Status of Revised Myriad-Mayo Guidance

During a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsels Committee (IPCC) fall conference, which took place this week in Nashville, TN, the U.S. Patent and Trademark Office provided a...more

11/13/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- BIO Joint Comment

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

10/24/2014 - AMP v Myriad Biotechnology Draft Guidance Genetic Materials Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Manufacturers Public Comment Trade Associations USPTO

Docs @ BIO: USPTO Provides Update on Myriad-Mayo Guidance

At last week's BIO International Convention in San Diego, Andrew Hirshfeld, USPTO Deputy Commissioner for Patent Examination Policy, and June Cohan, a Legal Advisor with the USPTO's Office of Patent Legal Administration, took...more

7/2/2014 - DNA Genetic Materials Guidance Update Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Public Comment Section 101 Stem cells USPTO

In re Roslin Institute (Fed. Cir. 2014) - Dolly the Sheep Not Patent Eligible Subject Matter

Earlier today, the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board affirming the rejection of claims 155-159 and 164 of U.S. Application No. 09/225,233 as being directed to unpatentable subject...more

5/9/2014 - Genetic Materials Myriad Patent-Eligible Subject Matter Patents USPTO

Top Three Stories of 2013

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/6/2014 - America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto DNA First-to-File First-to-Invent Genetic Materials Genetically Engineered Seed Human Genes Inventors Monsanto Patent Infringement Patent Litigation Patent Reform Patents Pharmaceutical SCOTUS

Sanofi-Aventis v. Pfizer Inc. (Fed. Cir. 2013)

Last week, in Sanofi-Aventis v. Pfizer Inc., the Federal Circuit affirmed an award of priority to Pfizer by the Board of Patent Appeals and Interferences in an interference involving the cDNA for the human interleukin-13...more

11/15/2013 - DNA Genetic Materials Human Genes Patent Litigation Patent-Eligible Subject Matter Patents Pfizer

23andMe Patent Creates Controversy

A patent issued to 23andMe, Inc. last month has created some controversy, and in response, the biotech company, based in Mountain View, California, has posted its side of the story on the 23andMe blog. The patent, U.S....more

10/9/2013 - 23andMe Biotechnology DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Patents

Authors of Genome Medicine Article Form Genetic Testing Company

In a paper published in March in the journal Genome Medicine, Dr. Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Dr. Christopher Mason of Cornell University contended that due to the...more

8/13/2013 - Biotechnology DNA Genetic Materials Genetic Testing Genome Project Human Genes Medical Research Patents Pharmaceutical

NIH Implements New Policy on HeLa Genomic Data

On Wednesday, the National Institutes of Health (NIH) announced that the agency had reached an understanding with the family of Ms. Henrietta Lacks regarding access to genomic data for the HeLa cell line, which was derived...more

8/9/2013 - Cancer DNA Genetic Materials Genetic Testing Human Genes NIH

NCI Researchers Generate Largest Database of Cancer-specific Genetic Variations

Last month, the American Association for Cancer Research (AACR) announced that researchers at the National Cancer Institute (NCI) had generated a data set of cancer-specific genetic variations, which the researchers were...more

8/7/2013 - Cancer Databases DNA Genetic Materials Human Genes Medical Research

Consortium Launches Public Database of BRCA Data

On June 13, the Genetic Alliance announced the launch of an initiative to fill the public information gap caused by the lack of available genetic information for the BRCA1 and BRCA2 genes. ...more

7/5/2013 - AMP v Myriad Biotechnology BRCA DNA Genetic Materials Genetic Services Genetic Testing Patents Pharmaceutical

13 Results
|
View per page
Page: of 1